✦ LIBER ✦

Elective palliative total hip replacement in a patient with lymphoma and advanced lung cancer

✍ Scribed by Katz, Jeffrey N. ;Brick, Gregory W. ;Rudd, Rima

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 59 KB
Volume: 59
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23927

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cetuximab in combination with carboplati

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer : A multicenter phase 2 study

✍ Chandra P. Belani; Marshall T. Schreeder; Ronald G. Steis; Richard A. Guidice; T 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

Toxicity report of a phase 1/2 dose-esca

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy

✍ Samuel Bral; Michaël Duchateau; Harijati Versmessen; Douwe Verdries; Benedikt En 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

Final survival and safety results from a

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

✍ David R. Spigel; Ming Lin; Vincent O'Neill; John D. Hainsworth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

## Abstract ## BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth factor receptor (EGFR) with a proven survival advantage for patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) who have failed a prior chemotherapy. This phase 3b, mult

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati